Elutia
Update in progressELUT (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Elutia Inc. develops drug-eluting biomatrix products for surgical reconstruction, operating in Women’s Health and Cardiovascular. Its lead programs, NXT-41 and NXT-41x, are biologic scaffolds with local antibiotic delivery. SimpliDerm is a human acellular dermal matrix for soft-tissue reconstruction. ProxiCor and Tyke are cardiac patch/matrix products for repairs and pericardial closure; VasCure supports peripheral vasculature. Sold to hospitals via independent agents. Formerly Aziyo Biologics; renamed 2023. Based in Gaithersburg, MD.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. C. Randal Mills Ph.D.
- Founded2015
- Employees25
- Websiteelutia.com
Identifiers
- ISINUS05479K1060
- FIGIBBG00BRBB838
- CIK0001708527